d*l
2 楼
查了查，是个传统药厂，懂行的可以评价评价
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the
discovery, development and commercialization of drugs for the treatment of
severe metabolic, psychiatric and oncologic disorders. The Company is
developing mifepristone, a compound that modulates the effects of cortisol
by acting as a competitive antagonist at the glucocorticoid receptor (GR).
As of December 31, 2016, it had discovered three structurally distinct
series of selective cortisol modulators, all of which share mifepristone's
affinity for GR but, unlike mifepristone, do not bind to the progesterone
receptor. It is conducting two clinical trials of its selective cortisol
modulator, CORT125134. One trial is investigating CORT125134 as a treatment
for patients with Cushing syndrome. The second trial is investigating the
combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane
) to treat patients with solid-tumor cancers.
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the
discovery, development and commercialization of drugs for the treatment of
severe metabolic, psychiatric and oncologic disorders. The Company is
developing mifepristone, a compound that modulates the effects of cortisol
by acting as a competitive antagonist at the glucocorticoid receptor (GR).
As of December 31, 2016, it had discovered three structurally distinct
series of selective cortisol modulators, all of which share mifepristone's
affinity for GR but, unlike mifepristone, do not bind to the progesterone
receptor. It is conducting two clinical trials of its selective cortisol
modulator, CORT125134. One trial is investigating CORT125134 as a treatment
for patients with Cushing syndrome. The second trial is investigating the
combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane
) to treat patients with solid-tumor cancers.
相关阅读